![Lan Huang](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lan Huang
Gründer bei
BEYONDSPRING INC.
Vermögen: 10 Mio $ am 31.05.2026
Profil
Lan Huang is the founder of Dalian Wanchun Biotechnology Co. Ltd., founded in 2010.
Dr. Huang was the founder of Paramax International, Inc., founded in 2008, and held the title Chief Risk Officer.
Dr. Huang is the founder of BeyondSpring, Inc., founded in 2013, and holds the title Chairman.
Dr. Huang is the founder of Wuxi Mtlh Biotechnology Co. Ltd., founded in 2007, and holds the title Director.
Dr. Huang is also the founder of Hubei Wanchun Biotechnology Co. Ltd.,Seed Therapeutics, Inc...
Dr. Huang currently holds the positions of Chairman & Chief Executive Officer at BeyondSpring Pharmaceuticals, Inc. and Director at Sincere Efforts Foundation, Inc. Formerly, Dr. Huang was a Trustee at Lawrence University from 2012 to 2015.
Dr. Huang completed undergraduate education at Lawrence University and earned a doctorate from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BEYONDSPRING INC. 14.71% | 01.04.2026 | 6’048’488 ( 14.71% ) | 10 Mio $ | 31.05.2026 |
Aktive Positionen von Lan Huang
| Unternehmen | Position | Beginn |
|---|---|---|
| BEYONDSPRING INC. | Gründer | 01.01.2013 |
Wuxi Mtlh Biotechnology Co. Ltd.
 Wuxi Mtlh Biotechnology Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops anti-cancer drugs | Gründer | 01.01.2007 |
BeyondSpring Pharmaceuticals, Inc.
 BeyondSpring Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative cancer therapies that improve clinical outcomes | Vorstandsvorsitzender | - |
Seed Therapeutics, Inc.
 Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Lan Huang
| Unternehmen | Position | Ende |
|---|---|---|
Lawrence University
 Lawrence University Other Consumer ServicesConsumer Services Functions as a College/University | Direktor/Vorstandsmitglied | 01.01.2015 |
Dalian Wanchun Biotechnology Co. Ltd. | Gründer | - |
Paramax International, Inc.
 Paramax International, Inc. Medical/Nursing ServicesHealth Services Provides clinical research services | Gründer | - |
Ausbildung von Lan Huang
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
13
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Lawrence University
Lawrence University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Paramax International, Inc.
Paramax International, Inc. Medical/Nursing ServicesHealth Services Provides clinical research services | Health Services |
BeyondSpring Pharmaceuticals, Inc.
BeyondSpring Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative cancer therapies that improve clinical outcomes | Health Technology |
BeyondSpring, Inc.
 BeyondSpring, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cancer therapies | Health Technology |
Wuxi Mtlh Biotechnology Co. Ltd.
Wuxi Mtlh Biotechnology Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops anti-cancer drugs | Health Technology |
Dalian Wanchun Biotechnology Co. Ltd. | |
Seed Therapeutics, Inc.
Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang. | Commercial Services |
Wählen Sie MarketScreener 
